Asia Pacific Molecular Diagnostics Market

The Asia Pacific molecular diagnostics market is projected to grow from USD 4.22 billion in 2026 to USD 7.58 billion by 2031, at a CAGR of 12.4%. The market growth is supported by the increasing demand for advanced diagnostic solutions, driven by a high burden of infectious diseases & cancer across the region. Further contributing to sustained market growth in this region are the continued expansion of healthcare infrastructure, rising healthcare expenditures, and the wider adoption of molecular diagnostic technologies.

In June 2025, QIAGEN N.V. (Netherlands) partnered with GENCURIX (South Korea) to co-develop oncology assays for the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics. The partnership marked a significant step in expanding the range of in vitro diagnostic assays available on the QIAcuityDx Four platform, thereby improving access to digital PCR-based diagnostic solutions.

In February 2024, Myriad Genetics, Inc. (US) collaborated with the National Cancer Center Hospital East (Japan) to evaluate the prognostic and predictive potential of molecular residual disease (MRD) testing. As part of the SCRUM-MONSTAR-SCREEN-3 study, Myriad’s ultra-sensitive Precise MRD test is being used to monitor circulating tumor DNA (ctDNA) over time in patients with various solid and hematological cancers.

To know about the assumptions considered for the study download the pdf brochure

Companies such as QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Danaher (US), Hologic, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Becton, Dickinson and Company (US), and Abbott (US) have adopted various strategies to expand their offerings and increase their market shares. These strategies include collaborations, acquisitions, development of new products, and contractual agreements, among other approaches.

Danaher (US) is a leading player in the Asia Pacific molecular diagnostics market, driven by its strong focus on innovative diagnostic solutions and scalable laboratory systems tailored for high-throughput testing as well as decentralized settings. The company’s core strengths lie in automation, operational efficiency, and system reliability, which align well with the increasing testing volumes and evolving requirements of the region’s healthcare landscape.

F. Hoffmann-La Roche Ltd. (Switzerland) is another leading company in the Asia Pacific molecular diagnostics market due to its strong and well-established molecular diagnostics portfolio and long-standing presence across healthcare systems. The company offers a broad range of molecular testing solutions covering infectious diseases, oncology, and companion diagnostics supported by reliable platforms & integrated workflows. Roche’s close alignment with clinical needs and focus on high-quality & standardized testing have enabled the widespread adoption of its molecular diagnostics solutions.

Market Ranking

bioMérieux (France), Illumina (US), Danaher (US), Thermo Fisher Scientific (US), and Roche (Switzerland) are some of the prominent players in this market, primarily owing to their diverse diagnostic portfolios and continuous technological developments.

Roche maintains a strong position through its integrated MDx portfolio, combining testing platforms, automation, and companion diagnostics. Danaher is well established in PCR-based molecular diagnostics, supported by a broad range of assays and automated systems that generate consistent demand for consumables. Illumina plays a central role in next-generation sequencing, with its platforms commonly used for cancer profiling, genetic testing, and advanced molecular analysis. bioMérieux is recognized for its focus on infectious disease diagnostics, providing solutions used for rapid & specific pathogen detection. Thermo Fisher Scientific contributes through its comprehensive molecular diagnostic offerings, including PCR and NGS platforms, reagents, and sample preparation solutions, supporting a wide range of molecular diagnostic applications.

Related Reports:

Asia Pacific Molecular Diagnostics Market by Product & Service (Kits, Instruments), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application [Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)] - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com